tetano
Editor, Senior Moderator
Eur J Pharmacol
. 2023 Sep 27;176061.
doi: 10.1016/j.ejphar.2023.176061. Online ahead of print. From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection
Pamela Cappelletti[SUP] 1 [/SUP], Giovanna Gallo[SUP] 2 [/SUP], Rachele Marino[SUP] 3 [/SUP], Sakthimala Palaniappan[SUP] 3 [/SUP], Massimo Corbo[SUP] 4 [/SUP], Carmine Savoia[SUP] 5 [/SUP], Marco Feligioni[SUP] 6 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) has been declared a new pandemic in March 2020. Although most patients are asymptomatic, those with underlying cardiovascular comorbidities may develop a more severe systemic infection which is often associated with fatal pneumonia. Nonetheless, neurological and cardiovascular manifestations could be present even without respiratory symptoms. To date, no COVID-19-specific drugs are able for preventing or treating the infection and generally, the symptoms are relieved with general anti-inflammatory drugs. Angiotensin-converting-enzyme 2 (ACE2) may function as the receptor for virus entry within the cells favoring the progression of infection in the organism. On the other hand, ACE2 is a relevant enzyme in renin angiotensin system (RAS) cascade fostering Ang1-7/Mas receptor activation which promotes protective effects in neurological and cardiovascular systems. It is known that RAS is composed by two functional countervailing axes the ACE/AngII/AT1 receptor and the ACE/AngII/AT2 receptor which counteracts the actions mediated by AngII/AT1 receptor by inducing anti-inflammatory, antioxidant and anti-growth functions. Subsequently an "alternative" ACE2/Ang1-7/Mas receptor axis has been described with functions similar to the latter protective arm. Here, we discuss the neurological and cardiovascular effects of COVID-19 highlighting the role of the stimulation of the RAS "alternative" protective arm in attenuating pulmonary, cerebral and cardiovascular damages. In conclusion, only two clinical trials are running for Mas receptor agonists but few other molecules are in preclinical phase and if successful these drugs might represent a successful strategy for the treatment of the acute phase of COVID-19 infection.
Keywords: CNS; COVID-19; CVS; Mas receptor agonist; RAS.
. 2023 Sep 27;176061.
doi: 10.1016/j.ejphar.2023.176061. Online ahead of print. From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection
Pamela Cappelletti[SUP] 1 [/SUP], Giovanna Gallo[SUP] 2 [/SUP], Rachele Marino[SUP] 3 [/SUP], Sakthimala Palaniappan[SUP] 3 [/SUP], Massimo Corbo[SUP] 4 [/SUP], Carmine Savoia[SUP] 5 [/SUP], Marco Feligioni[SUP] 6 [/SUP]
Affiliations
- PMID: 37775018
- DOI: 10.1016/j.ejphar.2023.176061
Coronavirus disease 2019 (COVID-19) has been declared a new pandemic in March 2020. Although most patients are asymptomatic, those with underlying cardiovascular comorbidities may develop a more severe systemic infection which is often associated with fatal pneumonia. Nonetheless, neurological and cardiovascular manifestations could be present even without respiratory symptoms. To date, no COVID-19-specific drugs are able for preventing or treating the infection and generally, the symptoms are relieved with general anti-inflammatory drugs. Angiotensin-converting-enzyme 2 (ACE2) may function as the receptor for virus entry within the cells favoring the progression of infection in the organism. On the other hand, ACE2 is a relevant enzyme in renin angiotensin system (RAS) cascade fostering Ang1-7/Mas receptor activation which promotes protective effects in neurological and cardiovascular systems. It is known that RAS is composed by two functional countervailing axes the ACE/AngII/AT1 receptor and the ACE/AngII/AT2 receptor which counteracts the actions mediated by AngII/AT1 receptor by inducing anti-inflammatory, antioxidant and anti-growth functions. Subsequently an "alternative" ACE2/Ang1-7/Mas receptor axis has been described with functions similar to the latter protective arm. Here, we discuss the neurological and cardiovascular effects of COVID-19 highlighting the role of the stimulation of the RAS "alternative" protective arm in attenuating pulmonary, cerebral and cardiovascular damages. In conclusion, only two clinical trials are running for Mas receptor agonists but few other molecules are in preclinical phase and if successful these drugs might represent a successful strategy for the treatment of the acute phase of COVID-19 infection.
Keywords: CNS; COVID-19; CVS; Mas receptor agonist; RAS.